272 related articles for article (PubMed ID: 19338355)
1. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
[TBL] [Abstract][Full Text] [Related]
2. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3β inhibitors targeting breast cancer: design, synthesis, biological evaluation, and
Eldehna WM; Al-Rashood ST; Al-Warhi T; Eskandrani RO; Alharbi A; El Kerdawy AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):270-285. PubMed ID: 33327806
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.
Ye Q; Mao W; Zhou Y; Xu L; Li Q; Gao Y; Wang J; Li C; Xu Y; Xu Y; Liao H; Zhang L; Gao J; Li J; Pang T
Bioorg Med Chem; 2015 Mar; 23(5):1179-88. PubMed ID: 25662701
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
Ye Q; Shen Y; Zhou Y; Lv D; Gao J; Li J; Hu Y
Eur J Med Chem; 2013 Oct; 68():361-71. PubMed ID: 23994329
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
Ye Q; Xu G; Lv D; Cheng Z; Li J; Hu Y
Bioorg Med Chem; 2009 Jul; 17(13):4302-12. PubMed ID: 19481464
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β.
Yang Z; Liu H; Pan B; He F; Pan Z
Org Biomol Chem; 2018 Jun; 16(22):4127-4140. PubMed ID: 29781013
[TBL] [Abstract][Full Text] [Related]
9. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.
Kim KH; Gaisina I; Gallier F; Holzle D; Blond SY; Mesecar A; Kozikowski AP
J Mol Model; 2009 Dec; 15(12):1463-79. PubMed ID: 19440740
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.
Zhang HC; White KB; Ye H; McComsey DF; Derian CK; Addo MF; Andrade-Gordon P; Eckardt AJ; Conway BR; Westover L; Xu JZ; Look R; Demarest KT; Emanuel S; Maryanoff BE
Bioorg Med Chem Lett; 2003 Sep; 13(18):3049-53. PubMed ID: 12941331
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and preliminary characterization of radioiodinated benzofuran-3-yl-(indol-3-yl)maleimide derivatives as potential SPECT imaging probes for the detection of glycogen synthase kinase-3β (GSK-3β) in the brain.
Ono M; Kitada A; Watanabe H; Miyazaki A; Kimura H; Saji H
J Labelled Comp Radiopharm; 2016 Jun; 59(8):317-21. PubMed ID: 27126914
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent and bioavailable GSK-3beta inhibitors.
Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
[TBL] [Abstract][Full Text] [Related]
14. Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells.
Schmöle AC; Brennführer A; Karapetyan G; Jaster R; Pews-Davtyan A; Hübner R; Ortinau S; Beller M; Rolfs A; Frech MJ
Bioorg Med Chem; 2010 Sep; 18(18):6785-95. PubMed ID: 20708937
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.
Kuo GH; Prouty C; DeAngelis A; Shen L; O'Neill DJ; Shah C; Connolly PJ; Murray WV; Conway BR; Cheung P; Westover L; Xu JZ; Look RA; Demarest KT; Emanuel S; Middleton SA; Jolliffe L; Beavers MP; Chen X
J Med Chem; 2003 Sep; 46(19):4021-31. PubMed ID: 12954055
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3β Inhibitors and Anti-Ischemic Agents.
Ye Q; Li Q; Zhou Y; Xu L; Mao W; Gao Y; Li C; Xu Y; Xu Y; Liao H; Zhang L; Gao J; Li J; Pang T
Chem Biol Drug Des; 2015 Oct; 86(4):746-52. PubMed ID: 25711384
[TBL] [Abstract][Full Text] [Related]
17. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of GSK-3beta ameliorates hepatic ischemia-reperfusion injury through GSK-3beta/beta-catenin signaling pathway in mice.
Xia YX; Lu L; Wu ZS; Pu LY; Sun BC; Wang XH
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):278-84. PubMed ID: 22672822
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth.
Song EY; Palladinetti P; Klamer G; Ko KH; Lindeman R; O'Brien TA; Dolnikov A
Exp Hematol; 2010 Oct; 38(10):908-921.e1. PubMed ID: 20540984
[TBL] [Abstract][Full Text] [Related]
20. GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line.
Dickey A; Schleicher S; Leahy K; Hu R; Hallahan D; Thotala DK
J Neurooncol; 2011 Aug; 104(1):145-53. PubMed ID: 21161565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
